Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021 Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is...

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European...

Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research...

ExCellThera announces UM171 mechanism of action MONTRÉAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...

Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of...